Reserve your spot today for these upcoming webcasts!

Jointly provided by:     This activity is supported by an independent educational grant from Pfizer, Inc. Track 1: Optimizing Patient Access to CDK 4/6 Inhibitors in the Armamentarium Against Metastatic Breast Cancer: Considerations for Managed Care Decision Makers and Payer Professionals Webcasts Complete! On-demand CE Archive available at: www.impactedu.net/mbcmanagement/ Track 2: Optimizing Patient Access to CDK 4/6 Inhibitors for the Treatment of HR+/HER2- Metastatic Breast Cancer: Payer Implications for the Oncology Provider to Consider Webcasts Complete! On-demand CE Archive available at: www.impactedu.net/treatingmbc/   Learn About Recent clinical trial data and real-world evidence relevant to the use of CDK 4/6 inhibitors Benefit design strategies that provide equal access to CDK 4/6i therapy Best practices that ensure delivery of high quality, evidence-based, multidisciplinary care   Expert Faculty Presenters Adam M. Brufsky, MD, PhD, FACP (Track 1) Professor of Medicine, University of Pittsburgh School of Medicine Associate Division Chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine's Department of Medicine Jeffrey Dunn, PharmD, MBA Chief Clinical Officer Cooperative Benefits Group Jane Lowe Meisel, MD (Track 2) Associate Professor of Hematology and Medical Oncology Associate Vice Chair of Faculty Development and Promotions Winship Cancer Institute at Emory University   Who Should Attend? The primary target audience for this initiative consists of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.   Statement of Need/Program Overview Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most common breast cancer subtype. Although endocrine therapy is usually effective initially, approximately 50% of HR+ patients develop resistance to this intervention, ultimately leading to disease recurrence. For patients with HR+/HER2-metastatic breast cancer (mBC), the addition of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors to ET limits estrogen-induced tumor cell proliferation, minimizes endocrine resistance, and leads to greater progression free survival (PFS) vs. ET alone. This activity will help enable managed care and payer professionals to better understand the relevant findings from randomized clinical trials and real-world evidence of CDK 4/6 inhibitors to accurately interpret current evidence to inform development of policies and management procedures that appropriately align patients and treatment in order to enhance access to therapy, augment delivery of high-quality care, and improve treatment outcomes.   Educational Objectives At the conclusion of this activity, participants should be able to demonstrate improved ability to: Review recent clinical trial data and real-world evidence relevant to the use of CDK 4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer Evaluate benefit design strategies that provide equal access to CDK 4/6i therapy to all appropriate HR+/HER2- mBC patients Discuss best practices that ensure delivery of high quality, evidence-based, multidisciplinary care similar to that delivered by academic or National Cancer Institute-designated cancer centers   Agenda Track 1: Optimizing Patient Access to CDK 4/6 Inhibitors in the Armamentarium Against Metastatic Breast Cancer: Considerations for Managed Care Decision Makers and Payer Professionals Introduction Jeffrey Dunn, PharmD, MBA CDK 4/6 Inhibitors in the Treatment of HR+/HER2- mBC: Assessing Real World and Clinical Evidence Adam M. Brufsky, MD, PhD, FACP Integration of Recent Clinical Data into the HR+/HER2- mBC Treatment Algorithm Jeffrey Dunn, PharmD, MBA Medical and Pharmacy Management Strategies for Optimal Patient Access to CDK 4/6 Inhibitors Jeffrey Dunn, PharmD, MBA Audience Q&A Session Key Takeaways and Closing Comments Track 2: Optimizing Patient Access to CDK 4/6 Inhibitors for the Treatment of HR+/HER2- Metastatic Breast Cancer: Payer Implications for the Oncology Provider to Consider Introduction Jeffrey Dunn, PharmD, MBA HR+/HER2- mBC and the Role of CDK 4/6 Inhibitors: Review of the Real World and Clinical Evidence Jane Lowe Meisel, MD Optimizing HR+/HER2- mBC Treatment Outcomes: Addressing Barriers to the Use of CDK 4/6 Inhibitors Jane Lowe Meisel, MD Using Collaborative Care to Enhance HR+/HER2- mBC Outcomes (case-based discussion) Jeffrey Dunn, PharmD, MBA and Jane Lowe Meisel, MD Audience Q&A Session Key Takeaways and Closing Comments   Accreditation Information Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician Continuing Medical Education The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Track 1: Optimizing Patient Access to CDK 4/6 Inhibitors in the Armamentarium Against Metastatic Breast Cancer: Considerations for Managed Care Decision Makers and Payer Professionals - 1.5 AMA PRA Category 1TM Credits Track 2: Optimizing Patient Access to CDK 4/6 Inhibitors for the Treatment of HR+/HER2- Metastatic Breast Cancer: Payer Implications for the Oncology Provider to Consider - 1.5 AMA PRA Category 1TM Credits Continuing Pharmacy Education Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Track 1: Optimizing Patient Access to CDK 4/6 Inhibitors in the Armamentarium Against Metastatic Breast Cancer: Considerations for Managed Care Decision Makers and Payer Professionals - 1.5 contact hours (0.15 CEUs) Universal Activity Number: JA4008162-9999-22-160-L01-P Type of Activity: Knowledge Track 2: Optimizing Patient Access to CDK 4/6 Inhibitors for the Treatment of HR+/HER2- Metastatic Breast Cancer: Payer Implications for the Oncology Provider to Consider - 1.5 contact hours (0.15 CEUs) Universal Activity Number: JA4008162-9999-22-161-L01-P Type of Activity: Knowledge Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Track 1: Optimizing Patient Access to CDK 4/6 Inhibitors in the Armamentarium Against Metastatic Breast Cancer: Considerations for Managed Care Decision Makers and Payer Professionals - 1.5 contact hours Track 2: Optimizing Patient Access to CDK 4/6 Inhibitors for the Treatment of HR+/HER2- Metastatic Breast Cancer: Payer Implications for the Oncology Provider to Consider - 1.5 contact hours Interprofessional Continuing Education This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change. Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity. Hardware/Software Requirements Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up. Fee Information No additional fee is required to attend this CPE/CME activity. If you have any questions, please call (215) 619-8812 or email info@impactedu.net.